What is GRML's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GRML?

P/E (TTM) is n/a and 52-week range is $2.82 to $27.48 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GRML figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GRML?

The company profile lists net income (TTM) near $-1.48B, EPS (TTM) near $-9.81 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Greenland Mines Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in Charlotte, North Carolina, US, 150.5M shares outstanding, ISIN US49876K1034 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Greenland Mines Ltd

$GRML

Health Care · Biotechnology

IR Run Scenarios

$5.17

-12.07%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Greenland Mines Ltd. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in Charlotte, North Carolina and currently employs 2 full-time employees. The company went IPO on 2022-04-29. The firm is focused is focused on the exploration and development of the Skaergaard Project. The company operates with two operating divisions Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. The company operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The firm holds, through its acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease).

Employees

Website

greenlandmines.com

IPO

2022-04-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)